Aims: This study aimed to investigate the effect of () gene mutation (identified from a hereditary multiple exostoses family) on chondrocyte proliferation and differentiation.
Methods: ATDC5 chondrocytes were cultured in insulin-transferrin-selenium medium to induce differentiation. Cells were transfected with pcDNA3.0 plasmids with either a wild-type (WT) or mutated (MUT) gene. The inorganic phosphate (Pi) concentration in the medium of cells was determined. The expression of markers of chondrocyte proliferation and differentiation, the Indian hedgehog (Ihh), and parathyroid hormone-related protein (PTHrP) pathway were evaluated by quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting.
Results: The expression of in MUT group was similar to WT group. The Pi concentration in the medium of cells in MUT group was significantly higher than WT group, which meant the mutation inhibited Pi uptake in ATDC5 chondrocytes. The proliferation rate of ATDC5 chondrocytes in MUT group was greater than WT group. The expression of aggrecan (Acan), α-1 chain of type II collagen (COL2A1), and SRY-box transcription factor 9 (SOX9) were higher in MUT group than WT group. However, the expression of Runt-related transcription factor 2 (Runx2), α-1 chain of type X collagen (COL10A1), and matrix metallopeptidase 13 (MMP13) was significantly decreased in the MUT group. Similar results were obtained by Alcian blue and Alizarin red staining. The expression of Ihh and PTHrP in MUT group was higher than WT group. An inhibitor (cyclopamine) of Ihh/PTHrP signalling pathway inhibited the proliferation and restored the differentiation of chondrocytes in MUT group.
Conclusion: A mutation in (c.C1948T) decreases Pi uptake in ATDC5 chondrocytes. mutation promotes chondrocyte proliferation while inhibiting chondrocyte differentiation. The Ihh/PTHrP signalling pathway may play an important role in this process. Cite this article: 2020;9(11):751-760.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649514 | PMC |
| http://dx.doi.org/10.1302/2046-3758.911.BJR-2020-0112.R1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Low-exhaustion peripheral circulating γδ T cells serve as a biomarker for predicting the clinical benefit rate of non-small cell lung cancer (NSCLC) patients to chemotherapy or targeted therapy: a single-center retrospective study.
BMC Cancer
January 2025
Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai People's Hospital Affiliated with Jinan University, Jinan University, Zhuhai, China.
Background: Multiple studies have demonstrated that the abundance and functionality of γδ T cells are favorable prognostic indicators for prolonged survival in cancer patients. However, the association between the immunophenotype of circulating γδ T cells and the therapeutic response in NSCLC patients undergoing chemotherapy or targeted therapy remains unclear.
Methods: Patients with EGFR wild-type (EGFR-WT) or mutant (EGFR-Mut) non-small cell lung cancer (NSCLC), diagnosed between January 2020 and January 2024, were included in this study.
Impact of EML4-ALK Variants and TP53 Status on the Efficacy of ALK Inhibitors in Patients With Non-small Cell Lung Cancer.
Thorac Cancer
January 2025
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: The clinical implications of different EML4-ALK fusion variants remain poorly elucidated in the era of second-generation ALK inhibitors.
Methods: This was a retrospective cohort study, wherein patients diagnosed with locally advanced or metastatic non-small cell lung cancer harboring EML4-ALK fusion were stratified into two cohorts based on their first-line treatment: Cohort 1 received alectinib, while Cohort 2 received crizotinib. Statistical analysis was employed to investigate the impact of different EML4-ALK variants and TP53 status on the efficacy of first-line ALK-TKIs.
Atrial remodeling is a major pathophysiological mechanism of atrial fibrillation (AF). Atrial remodeling progresses with aging and background diseases, including hypertension, heart failure, and AF itself. However, its mechanism of action and reversibility have not been completely elucidated.
View Article and Find Full Text PDFDiagnostic performance of multiparametric nonenhanced magnetic resonance imaging (MRI) in grading glioma and correlating IDH mutation status.
Clin Radiol
December 2024
Department of Radiology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, Shandong, 264200, China. Electronic address:
Aim: To evaluate the diagnostic performance of nonenhanced magnetic resonance imaging (MRI) in grading glioma and correlating isocitrate dehydrogenase (IDH) mutation status.
Materials And Methods: Patients with diagnoses confirmed by postoperative pathology were enrolled. Quantitative parameters, including the relative amide proton transfer-weighted (rAPTW), relative cerebral blood flow (CBF), and apparent diffusion coefficient (ADC) were applied to grade gliomas and correlate IDH mutation status.
PI3K/AKT/mTOR Activation is Associated with Malignant Severity and Poorer Prognosis in Parathyroid Carcinomas.
J Clin Endocrinol Metab
January 2025
Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Context And Objective: Parathyroid carcinoma (PCa) is a rare endocrine neoplasm known for its high recurrence. The specific molecular properties influencing the prognosis of PCa remain largely elusive. The present study was designed to explore the significance of PI3K/AKT/mTOR activation in PCa.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!